Northland analyst Carl Byrnes downgraded Nabriva Therapeutics to Underperform from Outperform with a price target of $1, down from $8, after the company announced that its board approved a plan to preserve cash in order to adequately fund an orderly wind down of the company’s operations following an assessment of strategic options.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBRV:
- Nabriva Therapeutics terminates agreement with Amplity Health
- Nabriva to terminate all employees not deemed necessary for wind-down
- Nabriva Therapeutics focused on sale of existing assets
- Nabriva to focus on preserving cash to fund wind down of operations
- Nabriva Therapeutics Provides Corporate Update
